Monash IVF lowers FY26 profit guidance

Monash IVF Group (ASX:MVF) has revised its financial outlook for the 2026 financial year, advising the market that it now forecasts an underlying net profit after tax of between $17 million and $18 million.

The primary catalyst for the downgraded earnings guidance is softer-than-anticipated activity across the Australian Assisted Reproductive Technology sector during the second half of the fiscal year.

According to recently released Medicare data, national stimulated cycle volumes contracted by 4.7% on a rolling three-month basis to the end of April compared to the prior corresponding period.

Management confirmed that these adverse macroeconomic conditions persisted throughout May and June.

Despite the broader industry slowdown, Monash IVF managed to expand its footprint, lifting its Australian stimulated cycle market share by 1% to a total of 20.1% on a rolling three-month basis.

Growth was further bolstered by the company's international operations, which are projected to deliver second-half volumes materially higher than last year.

The group continues to expand its clinical network under the guidance of newly appointed inaugural Chief Medical Officer, Fleur Cattrall, securing several key fertility specialists across Victoria and New South Wales.

While strategic cost-efficiency initiatives are well underway, CEO Victoria Atkinson noted that their financial impact on FY26 earnings remains limited due to implementation timing.

However, the measures are anticipated to yield more meaningful operational and financial contributions as the company moves into FY27.